Bill journey · stage 2 of 5
Under committee review
What it doesSummary passed house amended (Jun 12, 2018)
Abuse Deterrent Access Act of 2018
(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.
What just happenedJun 13, 2018
Received in the Senate and Read twice and referred to the Committee on Finance.
Who’s behind it
Received in the Senate and Read twice and referred to the Committee on Finance.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5061)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5061)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5582.
Considered under suspension of the rules. (consideration: CR H5061-5063)
Mr. Walden moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 556.
Committee on Ways and Means discharged.
Committee on Ways and Means discharged.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-721, Part I.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 115-721, Part I.
Ordered to be Reported (Amended) by Voice Vote.
Committee Consideration and Mark-up Session Held.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Abuse Deterrent Access Act of 2018
(Sec. 2) This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.
Abuse Deterrent Access Act of 2018
This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.
Abuse Deterrent Access Act of 2018
This bill requires the Centers for Medicare & Medicaid Services to report to Congress on the adequacy of access to abuse-deterrent opioid formulations for individuals with chronic pain enrolled in a prescription drug plan under Medicare or Medicare Advantage (MA). The report must account for any barriers preventing enrollees from accessing such formulations under Medicare or MA.